Establish and application of immunosenescence evaluation system in guiding clinical treatment of patients in urology

Comprehensive application of immunosenescence standardized evaluation system in guiding clinical treatment of patients in urology

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051410

Enrollment

Unknown

Registered

2021-09-23

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic hyperplasia, prostate cancer, chronic kidney disease stage V (uremia)

Interventions

Experimental group:The standardized evaluation system of immune aging was used for intervention and treatment

Control group:Conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients (over 18 years old) diagnosed with prostatic hyperplasia, prostate cancer and chronic kidney disease stage V (uremia); 2.Scheduled transurethral resection of prostate, radical prostatectomy and allograft kidney transplantation; 3.Surgical indications and no surgical contraindications.

Exclusion criteria

Exclusion criteria: 1.Have surgical contraindications; 2.Other surgeries are performed at the same time as the surgeries included in the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Complications;Wound healing time;Recovery time of intestinal function;The first time to get out of bed;Duration in hospital;Serum creatinine;Urine control condition;Disease progression;Patient survival rate;Transplanted kidney survival;	—

Countries

China

Contacts

Public ContactWei Qiang

West China Hospital of Sichuan University

weiqiang933@126.com+86 18980601425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026